In line Q4 sales; lower-than-expected 2024 guidance
08/02/24 -"Ipsen’s Q4 sales met expectations. Healthy growth in Oncology and a positive contribution from Rare Disease portfolio were somewhat offset by the decline in Neuroscience. Meanwhile, markets were ..."
Pages
55
Language
English
Published on
08/02/24
You may also be interested by these reports :
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...
10/09/26
After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of ...
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...